The reproductive and fertility wellness brand, OVUM, highlights the potential of artificial intelligence (AI) in revolutionizing the In vitro fertilization (IVF) field.
A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira
It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches.
February 14, 2024